What is Coagulation Reagent Market?
Coagulation test systems include both an instrument and a reagent (thromboplastin or partial thromboplastin). Coagulation tests measure the ability of blood to clot and how long it takes to clot. Tests can help the doctor assess the risk of excessive bleeding or clot formation (thrombosis) anywhere in the blood vessels. Coagulation reagents are great for measuring large areas to accurately detect abnormal results, with strong correlations with standard methods that ensure results are reliable. The main use of reagents is for the purpose of rapid diagnosis of various diseases caused by abnormal blood clotting/fibrinolysis, as well as more reliable reagents for measuring coagulation/fibrinolysis factors, their activators, and/or inhibitors, which are useful in deciding the course of treatment. With high stability for cost efficiency, the coagulation reagents are applicable to a wide range of analytical devices for clinical chemistry. Research and development of customer-specific reagents for coagulation-based in-vitro diagnostic devices are also carried out. Certain models are designed for use with human plasma in thrombin clotting time tests and are soluble in aqueous buffers or water.
Highlights from Coagulation Reagent Market Study
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Unit | Value (USD Million) |
Key Companies Profiled | Sclavo (Italy), Randox Laboratories (United Kingdom), Medirox AB (Sweden), Steellex Scientific Instrument Company (China), Operon Biotech (India), Sysmex Corporation (United States), Randox Laboratories Ltd. (United Kingdom), BioSystems Diagnostics Pvt. Ltd. (India), Transasia Bio-Medicals (India), Nihon Kohden (Japan), Robonik India Pvt Ltd. (India) and Sekisui Diagnostics (United States) |
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Coagulation Reagent market throughout the forecasted period.
Sclavo (Italy), Randox Laboratories (United Kingdom), Medirox AB (Sweden), Steellex Scientific Instrument Company (China), Operon Biotech (India), Sysmex Corporation (United States), Randox Laboratories Ltd. (United Kingdom), BioSystems Diagnostics Pvt. Ltd. (India), Transasia Bio-Medicals (India), Nihon Kohden (Japan), Robonik India Pvt Ltd. (India) and Sekisui Diagnostics (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Haemonetics Corporation (United States), Agappe diagnostics (Switzerland) and Rayto Life and Analytical Sciences Co. Ltd. (China). Coagulation Reagent Market Segmentation:
Scope | Sub-Segments |
---|
Application / End User | Hospitals, Research Institutes, Diagnostic Centers and Others |
Type | APTT, D-Dimer, Fibrinogen, Prothrombin and Others |
Technology | Mechanical,Electrochemical,Optical |
Packaging Type | Amber Glass Bottle,Plastic Bottle,Glass Bottle |
Grade | >90% Purity,>=97% Purity |
On the basis of geography, the market of Coagulation Reagent has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Reagent Rental Business and Emerging Markets and Rising Number of General Surgeries
Market Growth Drivers:
The Increasing Prevalence of Cardiovascular Diseases and Blood Disorders and The Rising Geriatric Population
Challenges:
Strict and Time-Consuming Regulatory Processes
Restraints:
High Cost Associated With the Coagulation Reagent
Opportunities:
Increasing Government Initiatives for the Improvement of Healthcare Infrastructure, Growth in Research Activities in Several Asia Pacific Countries and The Increased Innovations and Advancements in Technologies
Key Target Audience
Providers of Coagulation Reagent, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Market Leaders & Development Strategies
In 2022, Medirox announced that it merged with Nordic Biomarker. As a result of the merger, Nordic Biomarker is able to offer a wider range of high-quality reagents, calibrators, and controls for coagulation diagnostics.
In 2018, Sysmex had thereby launched the Automated Blood Coagulation Analyzers CN-6000 and CN-3000
In the United States, coagulation reagents are regulated by the Food and Drug Administration (FDA). The FDA requires that coagulation reagents be validated and meet certain performance standards before they can be marketed and sold for clinical use.